This form must be completed for all recipients who are randomized to the Comprehensive Report Form (CRF) track and whose primary disease is reported on the Pre-TED Disease Classification Form (Form 2402) as “Myeloproliferative Neoplasm (MPN) (1460)”. The Myeloproliferative Neoplasm (MPN) Post-HCT Data (Form 2157) must be completed in conjunction with each Post-HCT follow-up form completed (Form 2100). The form is designed to capture specific data occurring within the timeframe of each reporting period (i.e., between day 0 and day 100, between day 100 and the six-month date of contact, between the date of contact for the six-month follow up and the date of contact for the one-year follow up, etc.).

For recipients who had MPN that transformed to AML prior to transplant, only Form 2110 (Acute Myelogenous Leukemia Post-HCT Data) must be completed. Form 2057 (Myeloproliferative Neoplasm Pre-Infusion Data) is required to obtain MPN data pre-HCT, but Form 2157 (Myeloproliferative Neoplasm Post-HCT Data) is not required for these recipients.

Links to Sections of the Form:
Q1-86: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy
Q87-104: Post-HCT / Post-Infusion Therapy
Q105-201: Disease Detection Since the Date of Last Report
Q202-286: Disease Status at the Time of Evaluation for this Reporting Period

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please click here or reference the retired manual section on the Retired Forms Manuals webpage.

Date Manual Section Add/Remove/Modify Description
11/23/2020 2157: Myeloproliferative Neoplasm (MPN) Post-HCT Modify Instructions updated for question 281 on when to use the “not assessed” option for reporting they cytogenetic response: If cytogenetic response was not tested at the last evaluation time of best response to this line of therapy select “Not assessed” and continue with question 283.
10/5/2020 2157: Myeloproliferative Neoplasm (MPN) Post-HCT Add Clarification added on when to report “yes” and “no” for question 203: Report “yes” for question 203 and go to question 276 in any of the following scenarios:
  • Disease was detected by any method in the reporting period (reported in the Disease Detected Since the Date of Last Report, questions 105-181) and no therapy was given to treat disease between the date(s) of the assessments reported in the Disease Detection Since the Date of Last Report (questions 105-181) for the form and the date of contact for this reporting period the most recent disease assessments in the reporting period have already been reported in questions 105-202 (Disease Detection Since the Date of Last Report)
  • Disease was detected by any method in the reporting period (reported in the Disease Detection Since the Date of Last Report, questions 105-181), therapy was administered, but no assessments were performed after the initiation of therapy if assessments were reported in questions 105-202 (Disease Detection Since the Date of Last Report) and no therapy was given to treat disease between the date(s) of the reported assessments and the date of contact for this reporting period
    Report “no” for question 203 and report the most recent disease assessments in the reporting period in questions 204 – 275 in any of the following scenarios
  • Disease was not detected by any method of assessment during the reporting period
  • Disease was detected (color-red) in the reporting period (reported in the Disease Detected Since the Date of Last Report, questions 105-181), therapy was administered, and additional assessment(s) were performed after therapy by at least one method of assessment during the reporting period (reported in questions 105-202), but the most recent assessments have not yet been reported on the form
8/18/2020 2157: Myeloproliferative Neoplasm (MPN) Post-HCT Modify Blue information box added above questions 19, 117, and 214 to provide instructions on how to report CALR testing: If CALR testing was performed but the lab report does not specify the type, select “not done” for questions 25 and 26 and specify the results as either “positive” or “negative” for question 27.
8/18/2020 2157: Myeloproliferative Neoplasm (MPN) Post-HCT Modify Red warning box added above questions 262-23, explaining the question text is currently incorrect and will be revised with next revision of the form: The question text for questions 262 – 263 are incorrect. Currently, the question reads “Was disease detected via bone marrow examination;” however, the question should say “Was disease assessed via bone marrow examination.” This question will be updated with the next revision of this form.
8/18/2020 2157: Myeloproliferative Neoplasm (MPN) Post-HCT Modify Blue information box added above questions 19, 117, and 214 to provide instructions on how to report CALR testing: If CALR testing was performed but the lab report does not specify the type, select “not done” for questions 25 and 26 and specify the results as either “positive” or “negative” for question 27.
6/8/2020 2157: Myeloproliferative Neoplasm (MPN) Post-HCT Modify Updated the instructions for question 262 by as the instructions were incorrect. Indicate if disease was detected by a bone marrow examination. If disease was detected, If a bone marrow biopsy was performed at the time of evaluation for this reporting period, report “yes” for question 262 and report the date of the assessment in question 263. Continue with question 264.If the exact date is not known, use the process for reporting partial or unknown dates as described in the General Instructions, Guidelines for Completing Forms. If disease was detected on multiple bone marrow biopsies were performed during the reporting period, report the date of the assessment performed closest to the date of contact. If disease was not detected by a bone marrow examination biopsies were not performed at any time during the reporting period, or it is unknown if disease was detected any bone marrow biopsies were done, report “no” or “unknown” respectively and go to question 268.
6/3/2020 2157: Myeloproliferative Neoplasm (MPN) Post-HCT Add Provided clarification (see red text) on when to answer “not applicable” for questions 30 and 128. If testing for all of the listed driver mutations are negative, select “Not applicable (negative results).”
5/10/2020 2157: Myeloproliferative Neoplasm (MPN) Post-HCT Add Version 1 of the 2157: MPN Post-HCT section of the Forms Instruction Manual released. Version 1 corresponds to revision 1 of the Form 2157.
Last modified: Nov 23, 2020

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.